awmsg logo



nevirapine (Viramune®)


Reference No. 1581

Publication date:
27/07/2012


Last review date:
30/08/2016

Appraisal information

nevirapine (Viramune®) 50 mg prolonged-release tablet
nevirapine (Viramune®) 100 mg prolonged-release tablet
nevirapine (Viramune®) 400 mg prolonged-release tablet


Company: Boehringer Ingelheim Ltd
BNF category: Infections
NMG meeting date: 15/05/2012
AWMSG meeting date: 20/06/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1612
Ministerial ratification: 23/07/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets. Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used. Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download